JAF/TRB

PATENT COOPERATION TREATY

1 Tolli tile	, es pru		
INTERNATIONAL PRELIMINARY EX	AMINING AS BEING MAN	edria.	
To:	chae,	TONE	
INTERNATIONAL PRELIMINARY EX To: TERESA J. WELCH	RECEIVE		PCT
MICHAEL BEST & FREIDRICH.LLP			101
ONE SOUTH PINCKNEY STREET	NOA 5 0 50	006 NOTI	FICATION OF TRANSMITTAL OF
PO. BOX 1806	MOAFO	IN	TERNATIONAL PRELIMINARY
MADISON, WI 53701-1806		R	EPORT ON PATENTABILITY
	MADISON	NG (Chapte	er II of the Patent Cooperation Treaty)
	MANISON	W	(PCT Rule 71.1)
	MINES	Date of mailing	1011
		(day/month/year	16 NOV 2006
			<u></u>
Applicant's or agent's file reference			
013670-9003-WO00		IMPORTANT NOTIFICATION	
		(1 ()	I p
International application No.	International filing date (da	ty/montn/year)	Priority date (day/month/year)
PCT/US04/37932	12 November 2004 (12.11.2004)		14 November 2003 (14.11.2003)
Applicant		2004)	14 1(0VCIIIDEI 2003 (14.11,2003)
1			
INTEGRATED DNA TECHNOLOGIE	S. INC.		•

- The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary report on patentability and its annexes, if any, established on the international application.
- A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed invention is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the IPEA/ US

Mail Stop PCT, Attn: IPEA/US

Commissioner for Patents P.O. Box 1450

Alexandria, Virginia 22313-1450

Authorized officer

Fiona T. Powers James Form Telephone No. 571-272-1600

Facsimile No. (571) 273-3201

Form PCT/IPEA/416 (January 2004)

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or age	ent's file reference	FOR FURTHER ACT	TON	See Form PCT/IPEA/416
013670-9003-WC				
International appl		International filing date (a		Priority date (day/month/year)
PCT/US04/37932 12 November 2004 (12.11 International Patent Classification (IPC) or national classification and			14 November 2003 (14.11.2003)	
				21
PC: C09B 29/01(2007.01),29/08(2007.01);C12Q 1/68(2007.01);C07H 21/04(2007.01) USPC: 534/727,839;435/6				
Applicant				
INTEGRATED DNA TECHNOLOGIES, INC.				
		ional preliminary exami r Article 35 and transmitt		shed by this International Preliminary cording to Article 36.
2. This	2. This REPORT consists of a total of sheets, including this cover sheet.			
3. This	eport is also accomp	anied by ANNEXES, con	nprising:	
a. [sent to the applica	nt and to the Internationa	al Bureau) a total of _	sheets, as follows:
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).				
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.				
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s))				
, containing a sequence listing and/or tables related thereto, in electronic form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).				
4. This report contains indications relating to the following items:				
\boxtimes	Box No. i Ba	asis of the report		
	Box No. II Pr	iority		
		on-establishment of opinion with regard to novelty, inventive step and industrial oplicability		
	Box No. IV La	ack of unity of invention		
\boxtimes		easoned statement under Article 35(2) with regard to novelty, inventive step or dustrial applicability; citations and explanations supporting such statement		
	Box No. VI Co	ertain documents cited		
	Box No. VII Co	ertain defects in the international application		
	Box No. VIII Co	ertain observations on the	international applica	tion
Date of submission of the demand		Date of completion	of this report	
03 June 2005 (03.06.2005)		30 October 2006 (30.1	0.2006)	
Name and mailing address of the IPEA/ US		Authorized officer	0 1000	
Mail Stop PCT, Attn: IPEA/US Commissioner for Patents		Fiona T. Powers	Janice Force	
P.O. Box 1450 Alexandria, Virginia 22313-1450			Janue Ford	
Facsimile No. (571) 273-3201		Telephone No. 571-2	72-1600	
Form PCT/IPEA/409 (cover sheet)(April 2005)				

International application No.	
PCT/US04/37932	

Box No. I Basis of the report	
1. With regard to the language, this report is based on:	
the international application in the language in which it was filed.	
a translation of the international application into, which is the language of a translation furnished for the purposes of:	
international search (under Rules 12.3 and 23.1(b))	
publication of the international application (under Rule 12.4(a))	
international preliminary examination (under Rules 55.2(a) and/or 55.3(a))	
2. With regard to the elements of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):	
the international application as originally filed/furnished	
the description:	
pages 1-23 as originally filed/furnished pages* NONE received by this Authority on	
pages* NONE received by this Authority on	
the claims: pages 24-29 as originally filed/furnished	
pages* NONE as amended (together with any statement) under Article 19	
pages* NONE received by this Authority on	
pages* NONE received by this Authority on	
the drawings:	
pages 1/1 as originally filed/furnished	
pages* NONE received by this Authority on pages* NONE received by this Authority on	
a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.	
3. The amendments have resulted in the cancellation of:	
the description, pages NONE the claims, Nos. NONE the drawings, sheets/figs NONE the sequence listing (specify): NONE any table(s) related to the sequence listing (specify): NONE	
the claims, Nos. <u>NONE</u>	
the drawings, sheets/figs NONE	
the sequence listing (specify): NONE	
any table(s) related to the sequence listing (specify): NONE.	
4. This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).	
the description, pages	
the claims, Nos.	
the drawings, sheets/figs	
the sequence listing (specify):	
any table(s) related to the sequence listing (specify):	
* If item 4 applies, some or all of those sheets may be marked "superseded."	

Form PCT/IPEA/409 (Box No. V) (April 2005)

International application No. PCT/US04/37932

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
1. Statement			
Novelty (N)	Claims 4, 6, 7, 9, 10, 16, 19-41	YES	
	Claims 1-3, 5, 8, 11-15, 17, 18	3.70	
Inventive Step (IS)	Claims 4, 6, 7, 9, 10, 16, 19-41	YES	
,	Claims 1-3, 5, 8, 11-15, 17, 18		
Industrial Applicability (IA)	Claims 1.41	XITTO	
madstrai Applicability (IA)	Claims 1-41 Claims NONE		
2. Citations and Explanations (Rule 70.7) Please See Continuation Sheet			
		İ	

International application No.

PCT/US04/37932

Box No. VIII	Certain observations on the international application	
The following ob supported by the control of the co	servations on the clarity of the claims, description, and drawing description, are made:	gs or on the question whether the claims are fully
Claims 2, 20 and 21 are objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 6 because claims 2, 20 and 21 are indefinite for the following reason(s): in claim 2, R is not defined. In claims 20 and 21 CEP is not defined.		

Form PCT/IPEA/409 (Box No. VIII) (April 2005)

International application No.

PCT/US04/37932

Supplemental Box Relating to Sequence Listing			
Continuation of Box No. I, item 2:			
1. With regard invention, t	to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed his report was established on the basis of:		
a. type of n	naterial		
	a sequence listing		
	table(s) related to the sequence listing		
b. format o	f material		
\boxtimes	on paper		
\boxtimes	in electronic form		
c. time of f	iling/furnishing		
\boxtimes	contained in the international application as filed		
\boxtimes	filed together with the international application in electronic form		
	furnished subsequently to this Authority for the purposes of search and/or examination		
	received by this Authority as an amendment* on		
filed	ddition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been or furnished, the required statements that the information in the subsequent or additional copies is identical to that in application as filed or does not go beyond the application as filed, as appropriate, were furnished.		
3. Additional of	comments:		
* If item 4 in E "superseded."	Box No. I applies, the listing and/or table(s) related thereto, which form part of the basis of the report, may be marked		

International application No. PCT/US04/37932

Supplemental Box	
In case the space in any of the preceding boxes is not sufficient.	
Continuation of:	
V. 2. Citations and Explanations:	
Claims 1 to 3, 5, 8, 11 to 15, 17 and 18 lack novelty under PCT Article 3	3(2) as being anticipated by Hamprecht et al (DE
2546535) or Japanese Patent 52-91031.	
The references disclose the claimed chemical composition of the Formula 1 halogen, NO ₂ or CN and R ₇ is a substituted aryl group which is an anilyl group of t	he Formula 2 where L and L' are linking groups which
may be nonreactive and may comprise a hydroxyethyl group in which the hydroxy	group may be protected. Note Examples 1-17 of
Hamprecht et al. and the examples of JP 52-91031.	•
Claims I to 3, 5, 8, 11 and 12 lack novelty under PCT Article 33(2) as be	ring obvious over Japanese Patent 52-088681.

Claims 1, 2, 5, 8, 11 and 12 lack novelty under PCT Article 33(2) as being obvious over Elslager et al. (US 3218309). The reference discloses the claimed chemical composition of the Formula 1 wherein at least one of R_{1-6} is hydrogen and R_7 is a substituted aryl group which is a naphthyl group. Note column 8, lines 59 to 60.

The reference discloses the claimed chemical composition of the Formula 1 wherein R2 is an electron withdrawing group which is

Claims 1, 2, 5, 8, 11 to 15, 17 and 18 lack novelty under PCT Article 33(2) as being obvious over Ho et al.

The reference discloses the claimed chemical composition of the Formula 1 wherein at least one of R₁₋₆ is hydrogen and R₇ is a substituted aryl group which is an anilyl group of the Formula 2 wherein one of L and L' is a nonreactive linking group and the other is a hydroxyethyl group which may be protected. Note pages 6124-6125 NDR1M.

NO₂ and R₇ is a substituted aryl group which is a naphthyl group. Note the examples.

International application No. PCT/US04/37932

Supplemental Box

Claims 1 to 3, 5, 8, 11 to 15, 17 and 18 lack an inventive step under PCT Article 33(3) as being obvious over Hamprecht et al (DE 2546535) or Japanese Patent 52-91031.

The references disclose the claimed chemical composition of the Formula 1 wherein R_2 is an electron withdrawing group which is halogen, NO_2 or CN and R_7 is a substituted aryl group which is an anilyl group of the Formula 2 where L and L' are linking groups which may be nonreactive and may comprise a hydroxyethyl group in which the hydroxy group may be protected. Note Examples 1-17 of Hamprocht et al. and the examples of JP 52-91031. One of ordinary skill in the art would have been motivated to make additional compounds useful as dyes by modifying the linking groups of compounds disclosed by the references.

Claims 1 to 3, 5, 8, 11 and 12 lack an inventive step under PCT Article 33(3) as being obvious over Japanese Patent 52-088681.

The reference discloses the claimed chemical composition of the Formula 1 wherein R_2 is an electron withdrawing group which is NO_2 and R_7 is a substituted aryl group which is a naphthyl group. Note the examples. One of ordinary skill in the art would have been motivated to make additional compounds useful as dyes by modifying the linking groups of compounds disclosed by the reference.

Claims 1, 2, 5, 8, 11 and 12 lack an inventive step under PCT Article 33(3) as being obvious over Elslager et al. (US 3218309). The reference discloses the claimed chemical composition of the Formula 1 wherein at least one of R₁₋₆ is hydrogen and R₇ is a substituted aryl group which is a naphthyl group. Note column 8, lines 59 to 60. One of ordinary skill in the art would have been motivated to make additional compounds useful as dyes by modifying the linking groups of compounds disclosed by the reference.

Claims 1, 2, 5, 8, 11 to 15, 17 and 18 lack an inventive step under PCT Article 33(3) as being obvious over Ho et al.

The reference discloses the claimed chemical composition of the Formula 1 wherein at least one of R₁₋₆ is hydrogen and R₇ is a substituted aryl group which is an anilyl group of the Formula 2 wherein one of L and L' is a nonreactive linking group and the other is a hydroxyethyl group which may be protected. Note pages 6124-6125 NDR1M. One of ordinary skill in the art would have been motivated to make additional compounds useful as dyes by modifying the linking groups of compounds disclosed by the reference.

Claims 4, 6, 7, 9, 10, 16 and 19 to 41 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the compositions of the Formula 1 as defined by the claims, the method of hybridizing nucleic acid polymers or the method for synthesizing an oligonucleotide containing a fluorescent quenching composition.

Claims 1 to 41 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry.